Profile Get Profile for: Inovio Pharmaceuticals, Inc. 660 West Germantown Pike Suite 100 Plymouth Meeting, PA 19462 United States - Map Phone: 267-440-4200 Fax: 267-440-4242 Website: http://www.inovio.com Details Index Membership: N/A Sector: Healthcare Industry: Biotechnology Full Time Employees: 106 Business Summary Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company has collaborative development agreements with GeneOne Life Sciences to co-develop an Ebola vaccine through Phase I clinical trials; and The Wistar Institute for preventive and therapeutic DNA-based immunotherapy applications, as well as products for cancers and infectious diseases. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Developing DNA immunotherapies for cancers and infectious diseases http://www.inovio.com/products/ cancer trials http://www.inovio.com/clinical-trials/cancer-trials/
Authorized shares: 600M Outstanding Shares: 72.22M Float: 68.11M Something else that should be noted is that last i read, there were 3 companies (GSK - SNY - INO) in the race to produce the Zika Virus Vaccine. INO was in the lead with plans to initiate Phase 1 human testing before end of 2016.
The Biggest Threat to Inovio Pharmaceuticals, Inc. http://www.fool.com/investing/gener...gn=article&utm_medium=feed&utm_source=yahoo-2
Reported before open today (5/9/16) Earnings: EPS -$0.11 Revenue $8.1M Estimates: EPS -$0.23 Revenue $3.1M Up 6.25% today
yesterday I wanted to post the result but couldn't find the thread so I posted it on the daily http://finance.yahoo.com/news/inovio-ino-reports-narrower-expected-131501906.html
Inovio Pharmaceuticals Zika Vaccine Produces Robust Immune Responses in Non-Human Primates http://finance.yahoo.com/news/inovio-pharmaceuticals-zika-vaccine-produces-120000544.html
Inovio Pharmaceuticals' Zika Vaccine Takes a Big Step Forward There's good news for the biotech's Zika virus vaccine efforts from non-human primate testing. http://www.fool.com/investing/gener...gn=article&utm_medium=feed&utm_source=yahoo-2
Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed http://finance.yahoo.com/news/inovio-announces-fda-request-additional-120000050.html
Down 16% yesterday Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed Source: https://www.streetwisereports.com/pub/qmdata/47876
Analyst Upgrade/Downgrade Update Brokerage firm: Aegis Capital Change: Coverage Initiated Previous Rating: N/A Current Rating: Buy Previous Price Target: N/A Current Price Target: N/A
Inovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death - https://finance.yahoo.com/news/inovio-pharmaceuticals-zika-vaccine-protects-150000111.html
Science is slowly getting there Inovio Zika vaccine evokes robust response in early human study - https://finance.yahoo.com/news/inovio-zika-vaccine-evokes-robust-134431875.html
